Mode
Text Size
Log in / Sign up
Phase 2 N=13 Randomized Double-blind Treatment

Modafinil for Smoked Cocaine Self-Administration

Cocaine Dependence

Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcome: Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Modafinil 0 mg (Drug); Modafinil 200 mg (Drug); Modafinil 400 mg (Drug); Cocaine 0 mg (Drug); Cocaine 12 mg (Drug); Cocaine 25 mg (Drug); Cocaine 50 mg (Drug)
Age
Adult · 21+ yrs
Sex
All
Sponsor
New York State Psychiatric Institute
Primary completion
Mar 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Cocaine Self-administration
0; 0; 0; 2.2; 1.5; 2.1
SECONDARY
Drug Quality Cluster
2; 2; 2; 30; 28; 29
SECONDARY
Heart Rate
88; 86; 91; 102; 101; 97

Summary

Modafinil has been reported to reduce cocaine use in a clinical sample of infrequent users (2 days/week), but the effects of modafinil on cocaine self-administration in the laboratory have not been studied. The present study investigated the effects of modafinil maintenance on cocaine self-administration by frequent users (4 days/week) under controlled laboratory conditions. During this 48-day double-blind, crossover design study, the effects of modafinil maintenance (0, 200, and 400mg/day) on response to smoked cocaine (0, 12, 25, and 50 mg) were examined in nontreatment seeking cocaine-dependent individuals (n = 8).

Eligibility Criteria

Inclusion Criteria

  • Smokes cocaine
  • Has patterns of smoked cocaine use in terms of frequency and amount which parallel or exceed those administered in the study.
  • Age 21-50.
  • Able to give informed consent, and comply with study procedures.
  • Normal body weight Within normal weight range (for appropriate frame) according to 1983 Metropolitan Weight tables -

Exclusion Criteria

  • Current seizure disorder, heart disease or a history of serious adverse effects due to cocaine.
  • Dependence on substances (other than cocaine or nicotine) or a history of dependence on alcohol
  • Request for drug treatment
  • Judged to be noncompliant with study protocol.
  • Current use of any psychotropic medication.
  • Clinical laboratory tests outside normal limits that are clinically unacceptable to the study physician (BP > 140/90; BUN, creatinine, LFTs > 3x ULN; hematocrit < 34 for women, < 36 for men; pseudocholinesterase deficiency)
  • History of myocardial infarction or ischemia, clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
  • Currently meeting DSM-IV criteria for all major psychiatric/psychotic disorders other than transient psychosis due to drug abuse
  • Current parole or probation Self-report during interview -
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01778010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search